LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Teva Pharmaceutical Industries Ltd.

Suletud

SektorTervishoid

16.94 0.36

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

16.74

Max

17.1

Põhinäitajad

By Trading Economics

Sissetulek

495M

220M

Müük

-338M

3.9B

Aktsiakasum

0.52

Kasumimarginaal

5.654

Töötajad

37,000

EBITDA

502M

763M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+42.26% upside

Turustatistika

By TradingEconomics

Turukapital

1.8B

21B

Eelmine avamishind

16.58

Eelmine sulgemishind

16.94

Uudiste sentiment

By Acuity

41%

59%

143 / 382 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Teva Pharmaceutical Industries Ltd. Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

17. dets 2024, 19:39 UTC

Suurimad hinnamuutused turgudel

Correction to Teva Articles

17. dets 2024, 16:24 UTC

Suurimad hinnamuutused turgudel

Teva Soars, Sanofi Gains on Strong Trial Results for IBD Treatment

7. mai 2025, 17:01 UTC

Peamised uudised

Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says -- Barrons.com

17. dets 2024, 16:14 UTC

Omandamised, ülevõtmised, äriostud

These Stocks Are Moving the Most Today: Nvidia, Tesla, Broadcom, Pfizer, EVgo, Teva, SolarEdge, Affirm, and More -- Barrons.com

17. dets 2024, 13:51 UTC

Omandamised, ülevõtmised, äriostud

These Stocks Are Moving the Most Today: Nvidia, Tesla, Broadcom, Pfizer, EVgo, Teva, SolarEdge, Red Cat, and More -- Barrons.com

23. nov 2024, 12:00 UTC

Peamised uudised

Emerging-Markets Stocks Have Rarely Been So Hated. It's Time To Buy -- WSJ

22. aug 2024, 05:30 UTC

Peamised uudised

Generic Weight-Loss Drugs Won't Come for Years -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Teva Pharmaceutical Industries Ltd. Prognoos

Hinnasiht

By TipRanks

42.26% tõus

12 kuu keskmine prognoos

Keskmine 24 USD  42.26%

Kõrge 30 USD

Madal 20 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Teva Pharmaceutical Industries Ltd. 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

6 ratings

6

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

15.58 / N/AToetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Strong Bullish Evidence

Pikk perspektiiv

Bullish Evidence

Sentiment

By Acuity

143 / 382 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Teva Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.